Cefoperazone-Sulbactam

Cefoperazone-Sulbactam

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601206
ATC code	J01DD12 (WHO) Template:ATCvet
Pharmacokinetic data
Excretion	Hepatic
Identifiers
IUPAC name (6R,7R)-7-[(2R)-2-{[(4-Ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number	62893-19-0 Y
PubChem CID	44185
DrugBank	DB01329 Y
ChemSpider	40206 Y
UNII	7U75I1278D
KEGG	D07645 Y
ChEMBL	ChEMBL507674 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C25H27N9O8S2
Molar mass	645.67 g/mol
3D model (JSmol)	Interactive image
SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccc(O)cc3)NC(=O)N4C(=O)C(=O)N(CC)CC4)CSc5nnnn5C)C(=O)O
InChI InChI=1S/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1 Y Key:GCFBRXLSHGKWDP-XCGNWRKASA-N Y
(verify)

WikiDoc Resources for Cefoperazone-Sulbactam
Articles
Most recent articles on Cefoperazone-Sulbactam Most cited articles on Cefoperazone-Sulbactam Review articles on Cefoperazone-Sulbactam Articles on Cefoperazone-Sulbactam in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefoperazone-Sulbactam Images of Cefoperazone-Sulbactam Photos of Cefoperazone-Sulbactam Podcasts & MP3s on Cefoperazone-Sulbactam Videos on Cefoperazone-Sulbactam
Evidence Based Medicine
Cochrane Collaboration on Cefoperazone-Sulbactam Bandolier on Cefoperazone-Sulbactam TRIP on Cefoperazone-Sulbactam
Clinical Trials
Ongoing Trials on Cefoperazone-Sulbactam at Clinical Trials.gov Trial results on Cefoperazone-Sulbactam Clinical Trials on Cefoperazone-Sulbactam at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefoperazone-Sulbactam NICE Guidance on Cefoperazone-Sulbactam NHS PRODIGY Guidance FDA on Cefoperazone-Sulbactam CDC on Cefoperazone-Sulbactam
Books
Books on Cefoperazone-Sulbactam
News
Cefoperazone-Sulbactam in the news Be alerted to news on Cefoperazone-Sulbactam News trends on Cefoperazone-Sulbactam
Commentary
Blogs on Cefoperazone-Sulbactam
Definitions
Definitions of Cefoperazone-Sulbactam
Patient Resources / Community
Patient resources on Cefoperazone-Sulbactam Discussion groups on Cefoperazone-Sulbactam Patient Handouts on Cefoperazone-Sulbactam Directions to Hospitals Treating Cefoperazone-Sulbactam Risk calculators and risk factors for Cefoperazone-Sulbactam
Healthcare Provider Resources
Symptoms of Cefoperazone-Sulbactam Causes & Risk Factors for Cefoperazone-Sulbactam Diagnostic studies for Cefoperazone-Sulbactam Treatment of Cefoperazone-Sulbactam
Continuing Medical Education (CME)
CME Programs on Cefoperazone-Sulbactam
International
Cefoperazone-Sulbactam en Espanol Cefoperazone-Sulbactam en Francais
Business
Cefoperazone-Sulbactam in the Marketplace Patents on Cefoperazone-Sulbactam
Experimental / Informatics
List of terms related to Cefoperazone-Sulbactam

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cefoperazone is a third-generation cephalosporin antibiotic, marketed by Pfizer under the name Cefobid, and also marked by Pharco B International under the name Cefazone and also marketed by Sigmatec Pharmaceuticals under the name Cefoperazone. It is one of few cephalosporin antibiotics effective in treating Pseudomonas bacterial infections which are otherwise resistant to these antibiotics. Cefina-SB is a combination of sulbactam and cefoperazone. Cefoperazone exerts its bactericidal effect by inhibiting the bacterial cell wall synthesis, and sulbactam acts as a beta-lactamase inhibitor, to increase the antibacterial activity of cefoperazone against beta-lactamase-producing organisms. In some countries, the combination is sold as Sulperazone. Gepach International markets this combination of cefoperazone with sulbactam under the brand name Bacperazone.In India and SriLanka (Cefoperazone-Sulbactam) is manufacterd by Pfizer under the brand name of Magnex/Magnex-Forte depending on the Cefoperazone-Sulbactam ratio.

Spectrum of bacterial susceptibility

Cefoperazone has a broad spectrum of activity and has been used to target bacteria responsible for causing infections of the respiratory and urinary tract, skin, and the female genital tract. The following represents MIC susceptibility data for a few medically significant microorganisms.

• Haemophilus influenzae: 0.12 - 0.25 µg/ml
• Staphylococcus aureus: 0.125 - 32 µg/ml
• Streptococcus pneumoniae: ≤0.007 - 1 µg/ml

Adverse effects

Cefoperazone contains an N-methylthiotetrazole (NMTT or 1-MTT) side chain. As the antibiotic is broken down in the body, it releases free NMTT, which can cause hypoprothrombinemia (likely due to inhibition of the enzyme vitamin K epoxide reductase) and a reaction with ethanol similar to that produced by disulfiram (Antabuse), due to inhibition of aldehyde dehydrogenase.